Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an update.
Rhythm Biosciences Ltd has announced the appointment of Todd Perkinson as the new Chief Financial Officer. Perkinson brings extensive experience in financial management and business transformation, having successfully led major mergers, acquisitions, and business turnarounds in previous roles. His appointment comes as Rhythm prepares for significant global growth, indicating a strategic move to enhance its financial leadership and operational efficiency. This development is expected to strengthen Rhythm’s industry positioning and support its mission to expand its innovative cancer diagnostics solutions globally.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple and affordable blood tests for the early detection of cancers. The company aims to improve patient outcomes by detecting cancer at the earliest possible stage, thereby reducing the global burden of cancer and saving lives. Rhythm Biosciences collaborates with global partners to commercialize and distribute its solutions, and it was founded in 2017 with headquarters in Melbourne, Australia.
YTD Price Performance: -3.45%
Average Trading Volume: 347,823
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$24.37M
Learn more about RHY stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue